Trump comes out 766 million dollars, a new deal of influenza vaccine

The Trump administration has canceled a $ 766 million contract with Moderna to develop human bird flu vaccine, pharmaceutical company Advertise Wednesday.

The Biden administration signed $ 176 million deal With Moderna last year to develop a snapshot based on a morte targeting the virus that causes bird flu, H5N1. Then, earlier this year, the Ministry of Health and Humanitarian Services Biden Gave The pharmaceutical maker of an additional $ 590 million to develop the late vaccine and support clinical trials for five additional sub -types of H5N1.

Distinguished Minister of Health and vaccine Robert F. Kennedy She repeatedly expressed her fears On the safety of the messenger vaccines, though Save millions of lives. Just a week agoModerna withdrew its request to agree from the US Food and Drug Administration to obtain a mixed Covid-FLU vaccine, which is said to be more effective than either shooting on its own. Disease Control Center as well The vaccine recommendations are over Children and pregnant women.

Since 2022, more 148 million birds They were executed, and the virus spread to other wildlife, cows and humans. Until now, H5N1 hit 70 people in the United States – most of them farm workers – and they were killed, according to the United States Disease control and prevention centers. All over the world, the virus has about 50 % death, according to L. Global Health Organization.

“The cancellation means that the government ignores what might be one of the most effective and fast tools to combat the outbreak of bird influenza,” said Amish Adja, a researcher at the Johns Hopkins Health Security Center. Reuters. He added that the Trump administration followed the opposite approach to the speed of warp, which it launched to combat the Covid-19s.

In a statement, Moderna said it is planning to explore alternatives to the development of the late vaccine. On Wednesday, the company also announced the positive temporary experience data for its clinical studies in the late stage of the snapshot against H5N1.